Polaryx Therapeutics registers resale of 47.3M shares in direct listing; company gets no proceeds

Filed February 2, 2026 · ~1 min read

Key Changes

• high

  The offering is a direct listing resale of up to 47,343,297 shares by existing stockholders; Polaryx will not receive any proceeds from these sales.

  The Offering verify on EDGAR →
• medium

  A 1-for-4 reverse stock split was effected on January 12, 2026; all share and per-share data in the prospectus reflect the split.

  The Offering verify on EDGAR →
• medium

  Recent private placements were priced at $1.17 per share in 2024, $1.78 in mid-2025, and an average of $2.51 in late 2025.

  The Offering verify on EDGAR →